On September 22, 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), reported that two abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) were selected for presentation at upcoming international scientific conferences (Press release, TME Pharma, SEP 22, 2023, View Source [SID1234635346]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress taking place in Madrid, Spain, on October 20-24, 2023, will highlight an in-depth analysis of how the combination of radiotherapy and NOX-A12 remodels the immune tumor microenvironment in first-line glioblastoma patients, featuring clinical data from the GLORIA Phase 1/2 trial. The full abstract will be published online via the ESMO (Free ESMO Whitepaper) Congress website at 00.05 CEST on Monday, October 16, 2023. It will be available concurrently on the TME Pharma website.
Title: Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the Phase 1/2 GLORIA trial.
Speaker: Dr. Julian Layer
Session: Mini Oral 508MO
Lecture Time and Date: 11.15-11.20 a.m. CEST, Saturday, October 21, 2023
The 2023 Society for Neuro-Oncology (SNO) Annual Meeting, taking place in Vancouver, Canada, on November 15-19, 2023, will feature a poster presentation with a clinical update from the ongoing GLORIA Phase 1/2 trial studying NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and anti-VEGF (bevacizumab). The full abstract will be published and made available on the SNO official journal Neuro-Oncology on Friday, November 10, 2023. It will be available concurrently on the TME Pharma website.
Title: Interim data on dual inhibition of post-radiogenic angio-vasculogenesis by olaptesed pegol (NOX‑A12) and bevacizumab in glioblastoma from the first expansion arm of the Phase 1/2 GLORIA trial.
Presenter: Prof. Frank Giordano, MD
Session: Poster Session
Session Time and Date: 7.30-9.30 p.m. PT, Friday, November 17, 2023